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Overall, proton plans achieved lower dose for most of the 
OARs. Consequently, the NTCPs were significantly lower, 
p < 0.05. However, the variation, due to the model and 
radiobiological parameters choice, showed a significant 
impact on UTCP based on TCP/NTCP regarding medical 
decision. Similarly the variation of TCP/NTCP can reach 
20-30% and 100% for secondary cancer, depending on the 
model. 
Conclusion  
The considerable impact of radiobiological model on the 
radiotherapy outcomes urges us, once again, to measure 
specific (CTCAE scale) and global (QoL as EQ-5D) clinical 
outcomes, to tune the parameters of TCP/NTCP 
radiobiological models. On the other hand, a consensus on 
radiobiological parameters to compare and rank plans is 
highly advised in order to initiate real clinical trial instead 
of solely in-silico comparisons.  
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Purpose or Objective  
Craniospinal Irradiation (CSI) is the standard radiation 
therapy treatment for medulloblastoma. Conventional CSI 
photon therapy (Photon-CSI) delivers significant dose to 
surrounding normal tissues. Research into paediatric CSI 
with proton therapy (Proton-CSI) has increased, with the 
aim of exploiting the potential to reduce normal tissue 
dose and associated post-treatment complications. This 
review aims to compare treatment outcomes of paediatric 
medulloblastoma patients between Proton- and Photon-
CSI treatments. 
Material and Methods  
A search and review of studies published between 1990-
2015 comparing paediatric (2-18yrs) medulloblastoma 
Proton- and Photon-CSI in three aspects – normal organ 
sparing and target coverage, normal organ dysfunction 
and second malignancy risks – was completed. 
Results  
Fifteen studies were selected for review and the results 
were directly compared. Proton-CSI reported inconsistent 
target coverage improvements and improved out-of- field 
organ sparing was subjected to target volume definition 
and patient’s size. Normal organ dysfunction risks were 
predicted to be lower following increased normal tissue 
sparing with Proton-CSI. However, dysfunction can arise 
from indirect irradiation and predicted risks can be 
altered according to survivor’s future lifestyle habits. 
Secondary malignancy risks were generally lower with 
Proton-CSI based on several different risk models. In light 
of Proton-CSI and Photon-CSI delivering similar neural-axis 
dose, Proton-CSI might not significantly reduce secondary 
malignancy risks compared to Photon-CSI as documented 
secondary cancers were mainly from the brain. 
Conclusion  
Overall, Proton-CSI conferred better treatment outcomes 
than Photon-CSI for paediatric medulloblastoma patients. 
This review serves to compare the current literature in the 
absence of long term data from prospective studies. 
Proton-CSI should be used with caution while more 
prospective studies are awaited to reveal its true clinical 
benefit for paediatric medulloblastoma. 
 
EP-1382  Feasibility of Proton therapy with concomitant 
Chemotherapy for atypical teratoid rhabdoid tumors 
S. Peters1, M. Christiaens1, S. Schulz1, S. Frisch1, P.H. 
Kramer1, C. Blase2, M.C. Frühwald3, B. Timmermann1 
1University Hospital Essen, West German Proton Therapy 
Center, Essen, Germany 
2Anästhesie Netz Rhein-Ruhr, Anesthesia, Bochum, 
Germany 
3Children´s Hospital Augsburg, EU_RHAB Registry 
Center, Augsburg, Germany 
 
Purpose or Objective  
Atypical teratoid rhabdoid tumors (AT/RT) are a rare and 
highly aggressive disease mostly in infants. Therapy of 
affected patients requires an intensive multidimensional 
multimodality treatment concept of surgery, 
chemotherapy (CTX) and radiotherapy (RT) even in the 
very young patients. RT takes place either after the end 
of CTX or concomitant to CTX. Still, there is concern, that 
intensive combined treatment may not be feasible. We 
therefore aimed to investigate events of treatment 
prolongation and hospitalization during proton beam 
therapy (PT) and concomitant CTX.  
Material and Methods  
All patients treated at WPE with PT between 2013 and 
2016 were prospectively enrolled in the Registry Study for 
children (KiProReg). Informed consent was obtained from 
their legal representatives. All patients underwent weekly 
examinations by radiation and pediatric oncologists. Acute 
side effects according to CTCAE 4.0., time of 
hospitalization and prolongation of PT were documented. 
Hospitalization and treatment interruption was only taken 
into account if caused by complications. 
Results  
Twenty patients (6 females; 14 males) with a median age 
of 2.0 years at the start of PT (range, 1.0 - 8.0 years) were 
enrolled. Twelve patients received local PT up to 54 Gy 
only; six received an additional boost with a final dose of 
59.4 Gy; 2 received craniospinal irradiation plus local 
boost up to 55.6 Gy. 19 of them required deep sedation 
during PT.  Nine patients had concomitant chemotherapy 
(RCT) consisting of ifosfamide, carboplatinum, etoposide 
and/or vincristine, cyclophosphamide. Patients with RCT 
received an average of 1.4 cycles (range 1.0-3.0). Seven 
patients (35%) had an episode of fever; four of them 
received RCT. Acute toxicity during PT is displayed in 
graph 1. Nine patients (45%) had to be admitted of whom 
5 (25%) received concomitant CTX. The duration of 
hospitalization varied between one and 49 days (average 
9.7). Six patients were hospitalized for a period less than 
five days. Prolonged hospitalization in the three cases was 
caused by bad nutritional status present already before 
the start of PT, Norovirus infection and Staphylococcus 
epidermidis infection, respectively. Average 
hospitalization of patients with RCT was 3.0 days (range 
1.0-21.0 d) with PT only 5.5 days (range 1.0-49.0 d). In 
two patients (10%) PT had to be interrupted either three 
or four days. Reasons were viral respiratory infection in 
one case and bacterial port-a-cath and subsequent 




sepsis.  Both patients had not received concomitant CTX.
 
Conclusion  
Our evaluation did not reveal relevant prolongation of 
treatment due to RCT strategy when administering proton 
beam therapy in very young patients according to EU-
RHAB. However, experienced, multidisciplinary teams 
have to carefully accompany these very young patients in 
order to appropriately manage treatment complications 
and to avoid treatment interruptions potentially 
jeopardizing treatment efficacy. 
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Purpose or Objective  
Usually, evaluation of palliative radiotherapy is made by 
physical findings or levels of pain relief. But little is known 
about patient quality of life (QOL), psychophysiological 
response, and assessment of adverse effect from the view 
point of QOL. We evaluated the effects of palliative 
radiotherapy for cancer recurrence or metastasis on 
patient QOL and psychophysiology.  
Material and Methods  
A total of 67 patients who received palliative radiotherapy 
between 2014 and 2015 were enrolled. Patient diseases 
were bone metastasis in 51 patients, lymph node 
metastasis in 7 patients, brain metastasis in 2 patients, 
local recurrence in 3 patients, and the others in 4 patients. 
Median irradiated dose was 30 Gy in 10 fractions for 
palliative radiotherapy. We used the questionnaires 
EORTC-QLQ-C30 and EORTC-QLQ-C15-PAL to evaluate 
patient QOL and the Hospital Anxiety and Depression Scale 
(HADS) to evaluate patient mental healthcare at the start 
and at the end of radiotherapy.  
Results  
As compared to scores at the start of radiotherapy, at the 
end of radiotherapy, numerical rating scale (NRS) and face 
scale significantly decreased. On the other hand, Eastern 
Cooperative Oncology Group Performance Status (ECOG 
PS) did not show no changes during palliative 
radiotherapy. In functional scales, average scores of role 
functioning (RF2) and emotional functioning (EF) also 
improved. In symptom scales, average scores of fatigue 
(FA), pain (PA), and insomnia (SL) improved. In bone 
metastasis group, global health status / QOL (QL2), PA, 
and SL significantly improved. After palliative 
radiotherapy, anxiety score of HADS was elevated below 
age of 70 years. There was relationship between anxiety 
improvement and QOL improvement after palliative 
radiotherapy. Nausea and vomiting scores of EORTC-QLQ-
C15-PAL were associated with the irradiated volume of 
palliative radiotherapy for pelvic region. 
Conclusion  
Patient QOL of was improved by palliative radiotherapy 
regardless of PS. The possibility of palliative radiotherapy 
having a positive influence on patient psychophysiology 
was also suggested in younger age. 
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Purpose or Objective  
A large number of clinical trials studying immune 
checkpoint inhibitors exclude cancer patients who are on 
corticosteroids. This is based on the biological hypothesis 
that corticosteroids may antagonize the therapeutic 
effects of immunotherapy. Corticosteroids are routinely 
prescribed for their analgesic, antiemetic and anti-
inflammatory properties, such as in the palliation of 
metastatic disease to the central nervous system. We 
sought to review the literature looking at the clinical 
outcomes of patients with solid or hematologic cancers 
who are treated with immunotherapy and concomitant 
corticosteroids. 
Material and Methods  
Using Medline (via Ovid) and Embase (via Ovid), a 
literature search was performed from January 2000 to 
October 2, 2016 with no limits or language restrictions. 
Identified articles included variations of the terms 
immunotherapy drugs, steroids and cancer. These were 
found in the Title/Abstract/Keywords, and in the Medical 
Subject Headings (MeSH) and Emtree terms thesaurus. A 
validated adverse effects search filter was used to help 
with the retrieval of relevant results. A clinician reviewed 
all titles and abstracts. Full articles of selected studies 
were retrieved for further analysis of clinical/ radiological 
disease progression and survival outcomes. 
Results  
Following a retrieval of 3611 unique references, 155 
abstracts were retained for review. Twelve articles were 
retained for final analysis. The first nine articles/ 
abstracts consisted of case reports, case series and phase 
I-II trials of patients on CTLA-4 blockade therapy for 
metastatic melanoma and clear-cell renal cell carcinoma 
(RCC). Cohorts varied from 1 to 198 patients, including 
some patients with auto-immune disorders. They reported 
that the use of corticosteroids for the management of 
immune-related adverse events (irAEs) did not negatively 
impact objective clinical response. Of note, the above 
mentioned articles had not prospectively planned to 
analyze patient-related outcomes based on the use of 
corticosteroids. The tenth paper explored the use of 
colitis prophylaxis with Budesonide in patients receiving 
CTLA-4 blockade in a randomized phase II trial. In patients 
treated in the Budesonide arm, there was no statistically 
significant difference in oncologic outcomes. The final two 
publications describe objective clinical responses in 
patients treated with a combination of pembrolizumab, 
pomalidomide and dexamethasone for heavily treated 
relapsed/ refractory multiple myeloma patients.  
Conclusion  
The reviewed published data seems to suggest that the 
addition of corticosteroids to immunotherapy may not 
